advertisement
Abstract #10128 Published in IGR 6-1
The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%
Stewart WC; Stewart JA; Day DG; Jenkins JActa Ophthalmologica Scandinavica 2004; 82: 161-165
PURPOSE: To compare the efficacy and safety of unoprostone versus brimonidine both given twice daily in ocular hypertensive or primary open-angle glaucoma subjects. METHODS: After a one-month washout period a baseline diurnal curve was measured every two hours from 08.00 hours (trough) to 20.00 hours in subjects with a trough intraocular pressure (IOP) and the pressure 24 mmHg. Qualified subjects were randomized to either brimonidine or unoprostone. After six weeks of treatment the period one diurnal curve was performed. Subjects were then switched to the opposite treatment for six weeks and the period 2 diurnal curve was performed. RESULTS: A total of 33 subjects were included in this study. In the brimonidine-treated group the trough IOP 20.1 ± 2.8 mmHg was reduced from baseline up to eight hours after dosing. In the unoprostone-treated group the trough IOP was 19.5 ± 3.0 mmHg, which was statistically equal to that of brimonidine (p = 0.21), was reduced from baseline for 12 hours after dosing. Brimonidine decreased the IOP statistically more than unoprostone at 10.00 and 12.00 hours (p < 0.0001 and p = 0.02, respectively), while unoprostone reduced the IOP more than brimonidine at 18.00 and 20.00 hours (p = 0.002 and 0.05, respectively). Safety levels were similar between groups, but unoprostone caused more ocular stinging than brimonidine (p = 0.008). CONCLUSIONS: This study suggests that twice daily brimonidine demonstrates a statistically greater peak reduction in IOP than unoprostone. However, unoprostone, but not brimonidine, decreased IOP over the complete 12-hour daytime dosing cycle.
Dr. W.C. Stewart, Pharmaceutical Research Network, LLC, Charleston, SC 29412-2464, USA. info@prnorb.com
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)